Tag : plasminogen

Cardiology

Safety of low-dose prolonged infusion of tissue plasminogen activator therapy in patients with thromboembolic events in the intensive care unit.

Newsemia
Related Articles Safety of low-dose prolonged infusion of tissue plasminogen activator therapy in patients with thromboembolic events in the intensive care unit. Kardiologiia. 2020 Aug...
Cardiology

In peripartum cardiomyopathy Plasminogen Activator Inhibitor-1 is a potential new biomarker with controversial roles.

Newsemia
Related Articles In peripartum cardiomyopathy Plasminogen Activator Inhibitor-1 is a potential new biomarker with controversial roles. Cardiovasc Res. 2019 Nov 11;: Authors: Ricke-Hoch M, Hoes...
Cardiology

Intracoronary recombinant tissue plasminogen activator in an infant with hypoplastic left heart syndrome and complete left main coronary artery thrombosis.

Newsemia
Related Articles Intracoronary recombinant tissue plasminogen activator in an infant with hypoplastic left heart syndrome and complete left main coronary artery thrombosis. Catheter Cardiovasc Interv....
Neurology

Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.

Newsemia
Related Articles Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World. Cerebrovasc Dis. 2018 Nov 01;46(3-4):184-192...
Latest News

Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF: Data from the PREVEND study

Newsemia
Mulder, BA; Geelhoed, B; van der Harst, P; Spronk, HM; Van Gelder, IC; Asselbergs, FW; Rienstra, M; (2018) Plasminogen activator inhibitor-1 and tissue plasminogen activator...
Neurology

Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports

Newsemia
In the last decade, the novel oral anticoagulant (NOAC) dabigatran (a direct thrombin inhibitor), rivaroxaban, apixaban and edoxaban (direct factor Xa inhibitors) have been approved...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy